"
Triple Negative Breast Cancer Treatment: Use of Platinum and Platinum Analogs"
written by Manuela Fantini, Carlotta Santelmo, Fabrizio Drudi, Claudio Ridolfi, Eleonora Barzotti, Lorenzo Gianni, Valentina Arcangeli, Alessandra Affatato, Alberto Ravaioli,
published by
Journal of Cancer Therapy,
Vol.3 No.5A, 2012
has been cited by the following article(s):
[1]
|
Growth of Metastatic Triple-Negative Breast Cancer Is Inhibited by Deep Tumor-Penetrating and Slow Tumor-Clearing Chemotherapy: The Case of Tumor-Adhering Liposomes with Interstitial Drug Release
Molecular Pharmaceutics,
2020
DOI:10.1021/acs.molpharmaceut.9b00812
|
|
|
[2]
|
Growth of Metastatic Triple-Negative Breast Cancer Is Inhibited by Deep Tumor-Penetrating and Slow Tumor-Clearing Chemotherapy: The Case of Tumor-Adhering Liposomes with Interstitial Drug Release
Molecular Pharmaceutics,
2020
DOI:10.1021/acs.molpharmaceut.9b00812
|
|
|
[3]
|
Interstitial Release of Cisplatin from Triggerable Liposomes Enhances Efficacy against Triple Negative Breast Cancer Solid Tumor Analogues
Molecular Pharmaceutics,
2016
DOI:10.1021/acs.molpharmaceut.6b00439
|
|
|
[4]
|
Interstitial Release of Cisplatin from Triggerable Liposomes Enhances Efficacy against Triple Negative Breast Cancer Solid Tumor Analogues
Molecular Pharmaceutics,
2016
DOI:10.1021/acs.molpharmaceut.6b00439
|
|
|